YEZTUGO administration availability in NYC

Ask the selected service for the next available appointment for YEZTUGO PrEP assessment. Confirm whether booking or a walk-in visit is appropriate before traveling. The first visit reviews eligibility, records and the treatment plan. Medication delivery, authorization and an injection appointment may need separate coordination.

Bring previous HIV and STI results, your current prevention regimen, last injection date if applicable and insurance information. Ask how the next-day tablets will be obtained and how to contact the team if you cannot take them. Confirm medication receipt and testing arrangements before an administration visit. The label describes abdominal injections and an alternative thigh site; the administrator chooses an appropriate site using the current instructions.

At initiation, a negative antigen/antibody test is confirmed with HIV RNA testing, even if RNA returns after treatment starts. Before continuation, a negative rapid antigen/antibody test requires confirmation with a more sensitive assay. The clinician determines the complete testing approach and reviews symptoms and any ambiguous results.

Provide every prescription, over-the-counter medicine and supplement. Some strong or moderate CYP3A inducers require additional clinician-directed dosing under the August 2026 label; other starting combinations have no recommended regimen. Your prescriber must review the actual medicines and sequence.

The labeled start includes two subcutaneous injections and oral tablets on the first day, followed by oral tablets the next day. Those tablets are part of required initiation, not an optional tolerability trial. A trained professional administers the injections.

Continuation injections are scheduled every 26 weeks with a two-week allowance on either side. Agree on HIV testing, STI screening and what to do before travel or an access delay.

Ask separately about tablet coverage, injectable medication coverage, laboratory testing and administration charges. The supply may require authorization and shipment to an administration site. Assistance programs have eligibility rules and do not prove that a particular clinic or insurer participates. Keep a written transition plan while these steps are completed; confirm actual availability before traveling to a listed location.

Yeztugo is lenacapavir for prevention of sexually acquired HIV-1 in people who do not have HIV. Treatment starts with injections and tablets, then continues with injections about every six months. It can suit someone who prefers fewer medication visits, provided testing and follow-up remain reliable. Twice-yearly medication does not mean twice-yearly attention to every health concern: a new exposure, symptoms, STI screening or a medication change can require contact sooner.

The approved PrEP indication is for adults and adolescents weighing at least 35 kg who are at risk of acquiring HIV through sex. HIV-negative status must be established. Recent exposure, acute viral symptoms, past PrEP/PEP, pregnancy or breastfeeding and all current medicines belong in the evaluation. HIV testing is required before starting and before each injection. A positive or unknown HIV status prevents use as PrEP.

At initiation, a negative antigen/antibody test is confirmed with HIV RNA testing, even if RNA returns after treatment starts. Before continuation, a negative rapid antigen/antibody test requires confirmation with a more sensitive assay. The clinician determines the complete testing approach and reviews symptoms and any ambiguous results.

Provide every prescription, over-the-counter medicine and supplement. Some strong or moderate CYP3A inducers require additional clinician-directed dosing under the August 2026 label; other starting combinations have no recommended regimen. Your prescriber must review the actual medicines and sequence.

The labeled start includes two subcutaneous injections and oral tablets on the first day, followed by oral tablets the next day. Those tablets are part of required initiation, not an optional tolerability trial. A trained professional administers the injections.

Continuation injections are scheduled every 26 weeks with a two-week allowance on either side. Agree on HIV testing, STI screening and what to do before travel or an access delay.

No. Oral tablets on both initiation days are part of the labeled regimen. Contact your clinician immediately if the second-day tablets are unavailable, missed or vomited; do not improvise replacement doses.

The exact plan must be checked for both formulations, the dispensing route and administration site. Also ask about visits and laboratory charges. Another person’s approval or copay is not a reliable estimate of yours.

A clinician can compare options and make a transition plan based on HIV results, last doses, exposure and interactions. Keep the existing prevention plan until you receive explicit instructions; changing products without coordination can leave a gap.